Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668898 · ClinicalTrials.gov registry record
LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 203
- Enrollment target
NCT04668898: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT04668898 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 203 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04668898 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 203 participants
- Enrollment target
Study Summary
Single site observational study focused on elucidating the genes and biochemical pathways involved in causing Parkinson disease.
Primary Outcome
Discovery and validation of new blood-based genetic biomarkers (both DNA and expression-based) for Parkinson's disease
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2025-04-01 |
What the finished NCT04668898 record still lists
NCT04668898 is an observational study that tracks outcomes without assigning an intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04668898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04668898 about?
NCT04668898 is a clinical study titled "LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease". Single site observational study focused on elucidating the genes and biochemical pathways involved in causing Parkinson disease.
What is the current status of trial NCT04668898?
This trial is currently completed. The enrollment target is 203 participants. The study started on 2019-04-01. Estimated completion is 2025-04-01.
Who is sponsoring clinical trial NCT04668898?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI